<DOC>
	<DOCNO>NCT02461602</DOCNO>
	<brief_summary>ELITE ( Eliminate Thromboembolism : Improving Anticoagulation Non-valvular Atrial Fibrillation Patients ) two year research project ass warfarin management issue face atrial fibrillation ( AF ) patient ambulatory setting .</brief_summary>
	<brief_title>Eliminate Thromboembolism : Improving Anticoagulation Non-valvular Atrial Fibrillation Patients</brief_title>
	<detailed_description>ELITE prospective , multicenter observational study 500 participant characterize demographic , comorbidities , risk profile , socioeconomic status , patient preference relate anticoagulation management . The primary study endpoint warfarin discontinuation without resumption document medical record . Secondary outcomes interest include warfarin adherence factor associate suboptimal adherence and/or permanent discontinuation . Clinical data , include demographic , medical history , comorbidities , abstract entered site coordinator . An internal survey develop Duke Clinical Research Institute ( DCRI ) administer patient regularly schedule clinic visit . Survey item include patient treatment priority , perceive risk bleed and/or stroke , barrier adherence , treatment satisfaction . Subjects complete survey baseline followup visit close 6 month enrollment . This study provide foundation numerous potential future question medication adherence barrier treatment , survey physician preferences/ share decision-making ( concordance physician patient preference ) , followup capture clinical event , intervention improve long-term medication adherence AF .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<criteria>18 year old time enrollment Electrocardiographically confirm AF Able complete patientreported outcome survey Initiated warfarin therapy prior 3 month Ability adhere regular clinical visit Ability sign inform consent Ability read/comprehend/speak English Anticipated life expectancy less six month ( determine site investigator ) Transient AF secondary reversible condition ( hyperthyroidism , pulmonary embolism , postcardiothoracic surgery ) Recent Deep Venous Thrombosis ( DVT ) Pulmonary Embolism ( PE ) ( within 6 month ) Participation randomize trial anticoagulation AF Use home international normalize ratio ( INR ) monitoring system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Warfarin</keyword>
</DOC>